Why the study?
Does Lipoprotein-associated phospholipase A2 (Lp-PLA2) activity predict coronary artery disease in individuals with type 1 diabetes and macroalbuminuria?
Does Lipoprotein-associated phospholipase A2 (Lp-PLA2) activity predict coronary artery disease in individuals with type 1 diabetes and macroalbuminuria?
In individuals with type 1 diabetes and macroalbuminuria, the association between Lp-PLA2 activity and CAD is modified by CRP levels and haptoglobin genotype.
Should not yet change CAD risk assessment in type 1 diabetes with macroalbuminuria; leaves open CRP-modified Lp-PLA2 effects.
Given the paucity of data in type 1 diabetes concerning lipoprotein-associated phospholipase A( 2) (Lp-PLA(2)), we examined its prospective relationship with coronary artery disease (CAD), as well as the effect of modification by C-reactive protein (CRP) and haptoglobin genotype, in individuals with type 1 diabetes who are at an increased risk for CAD due to also having macroalbuminuria (n=96). Although Lp-PLA(2) activity was univariately predictive of CAD (HR=1.54 per SD, p=0.009), this relationship was not significant after covariate adjustment (p=0.59). There was a significant interaction between Lp-PLA(2) and CRP (p=0.02), i.e. those with both markers greater than the median level were more likely to have a CAD event than those persons with low levels of both (HR=2.89, p=0.06). When stratified by haptoglobin genotype, Lp-PLA(2) was predictive of CAD in persons with the 2/1 (HR=2.40, p=0.05), but not 2/2 (HR=0.66, p=0.27), genotype. The association between Lp-PLA(2) activity and CAD differs by CRP and haptoglobin genotype in this group of persons with type 1 diabetes and macroalbuminuria.
No takes yet. Share an insight, caveat, or question.
Miller et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: